News & Updates
Filter by Specialty:
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRASG12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
19 Jun 2023
BNT162b2 booster protects against COVID-19 infection, hospitalization in adolescents
In a national cohort study in Singapore, a booster dose of BNT162b2 maintained individual protection against severe COVID-19 disease among adolescents aged 12–17 years.
BNT162b2 booster protects against COVID-19 infection, hospitalization in adolescents
13 Jun 2023
Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC
In individuals with resectable non-small-cell lung cancer (NSCLC), the addition of perioperative durvalumab to neoadjuvant chemotherapy improved pathologic complete response (pCR) and event-free survival (EFS), findings from the AEGEAN study have shown.
Perioperative durvalumab-based regimen improves outcomes in resectable NSCLC
12 Jun 2023
Upfront osimertinib matches sequential treatment for prolonging survival in EGFR-mutant NSCLC
Patients with nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation appear to experience similar survival outcomes with either frontline osimertinib therapy or sequential treatment approach of gefitinib followed by osimertinib, although upfront osimertinib leads to a significant reduction in the risk of brain progression, as shown in the results of the APPLE trial presented at ELCC 2023.